Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Aug, 2014 | Pages:
80 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)
Opium (Opioid) Addiction - Pipeline Review, H2 2014 Summary Global Markets Direct's, 'Opium (Opioid) Addiction - Pipeline Review, H2 2014', provides an overview of the Opium (Opioid) Addiction's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Opium (Opioid) Addiction, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Opium (Opioid) Addiction and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Opium (Opioid) Addiction - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Opium (Opioid) Addiction and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Opium (Opioid) Addiction products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Opium (Opioid) Addiction pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Opium (Opioid) Addiction - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Opium (Opioid) Addiction pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 5 List of Figures 6 Introduction 7 Global Markets Direct Report Coverage 7 Opium (Opioid) Addiction Overview 8 Therapeutics Development 9 Pipeline Products for Opium (Opioid) Addiction - Overview 9 Pipeline Products for Opium (Opioid) Addiction - Comparative Analysis 10 Opium (Opioid) Addiction - Therapeutics under Development by Companies 11 Opium (Opioid) Addiction - Therapeutics under Investigation by Universities/Institutes 13 Opium (Opioid) Addiction - Pipeline Products Glance 14 Clinical Stage Products 14 Early Stage Products 15 Opium (Opioid) Addiction - Products under Development by Companies 16 Opium (Opioid) Addiction - Products under Investigation by Universities/Institutes 17 Opium (Opioid) Addiction - Companies Involved in Therapeutics Development 18 Alkermes Plc 18 Nanotherapeutics, Inc. 19 Acura Pharmaceuticals, Inc. 20 Catalyst Pharmaceutical Partners, Inc. 21 INSYS Therapeutics, Inc. 22 Camurus AB 23 Omeros Corporation 24 D&A Pharma SAS 25 Reckitt Benckiser Pharmaceutical, Inc. 26 AllTranz, Inc. 27 Relmada Therapeutics, Inc. 28 Celtic Pharmaceutical Holdings L.P. 29 Foresee Pharmaceuticals, LLC 30 Opium (Opioid) Addiction - Therapeutics Assessment 31 Assessment by Monotherapy Products 31 Assessment by Combination Products 32 Assessment by Target 33 Assessment by Mechanism of Action 36 Assessment by Route of Administration 39 Assessment by Molecule Type 41 Drug Profiles 43 TA-CD - Drug Profile 43 Product Description 43 Mechanism of Action 43 R&D Progress 43 buprenorphine hydrochloride - Drug Profile 44 Product Description 44 Mechanism of Action 44 R&D Progress 44 RBP-6300 - Drug Profile 45 Product Description 45 Mechanism of Action 45 R&D Progress 45 Cannabidiol - Drug Profile 46 Product Description 46 Mechanism of Action 46 R&D Progress 46 OMS-405 - Drug Profile 47 Product Description 47 Mechanism of Action 47 R&D Progress 47 MAL - Drug Profile 48 Product Description 48 Mechanism of Action 48 R&D Progress 48 samidorphan - Drug Profile 49 Product Description 49 Mechanism of Action 49 R&D Progress 49 (buprenorphine hydrochloride + naloxone hydrochloride) - Drug Profile 50 Product Description 50 Mechanism of Action 50 R&D Progress 50 CPP-115 - Drug Profile 51 Product Description 51 Mechanism of Action 51 R&D Progress 51 OMS-527 - Drug Profile 53 Product Description 53 Mechanism of Action 53 R&D Progress 53 buprenorphine hydrochloride ER - Drug Profile 55 Product Description 55 Mechanism of Action 55 R&D Progress 55 Vaccine for Opium Addiction - Drug Profile 56 Product Description 56 Mechanism of Action 56 R&D Progress 56 Cannabidiol - Drug Profile 57 Product Description 57 Mechanism of Action 57 R&D Progress 57 FP-004 - Drug Profile 58 Product Description 58 Mechanism of Action 58 R&D Progress 58 methadone IR - Drug Profile 59 Product Description 59 Mechanism of Action 59 R&D Progress 59 buprenorphine hydrochloride - Drug Profile 60 Product Description 60 Mechanism of Action 60 R&D Progress 60 Synthetic Peptides to Activate DOR and MOR and Inhibit MRP-1 for Oncology and Morphine Addiction - Drug Profile 61 Product Description 61 Mechanism of Action 61 R&D Progress 61 Synthetic Peptides to Inhibit Mu Opioid, Delta Opioid and MRP-1 for Oncology and Morphine Addiction - Drug Profile 62 Product Description 62 Mechanism of Action 62 R&D Progress 62 naltrexone - Drug Profile 63 Product Description 63 Mechanism of Action 63 R&D Progress 63 Opium (Opioid) Addiction - Recent Pipeline Updates 64 Opium (Opioid) Addiction - Dormant Projects 68 Opium (Opioid) Addiction - Discontinued Products 69 Opium (Opioid) Addiction - Product Development Milestones 70 Featured News & Press Releases 70 Aug 18, 2014: MediciNova Announces Positive Interim Results of Phase 2a Study of MN-166 (ibudilast) in Opioid Dependence 70 Jan 15, 2014: Collegium Pharmaceutical Announces Positive Topline Results of Human Abuse Potential Study Evaluating Intranasal Administration of Crushed Oxycodone DETERx, an Abuse-Deterrent, Extended-Release Product 71 Dec 05, 2013: Elite Pharmaceuticals Initiates Pilot Bioequivalence Study for ELI-201 72 Jul 29, 2013: Signature Therapeutics Receives BrIDGs Award to Advance Its Abuse-Deterrent Oxycodone, PF614 73 Jul 18, 2013: Collegium Pharmaceutical Announces Notice of Allowance for U.S. Patent Covering Oxycodone DETERx, an Abuse-Deterrent, Extended-Release Opioid Product 74 Mar 20, 2013: MediciNova Presents Phase Ib/IIa Study Data Of Ibudilast At American Academy Of Neurology Annual Meeting 74 Feb 12, 2013: Collegium Pharma Announces Notice Of Allowance For US Patent Covering Oxycodone DETERx Extended-release Opioid Product 76 Jan 03, 2013: MediciNova Provides Development Update On MN-166 77 Nov 20, 2012: MediciNova Initiates Phase IIa Trial Of MN-166 In Opioid Abusers 77 Nov 08, 2012: Catalyst Pharma Announces Top-Line Results Of CPP-109 Phase IIb Trial For Cocaine Addiction 78 Appendix 79 Methodology 79 Coverage 79 Secondary Research 79 Primary Research 79 Expert Panel Validation 79 Contact Us 80 Disclaimer 80
List of Tables Number of Products under Development for Opium (Opioid) Addiction, H2 2014 9 Number of Products under Development for Opium (Opioid) Addiction - Comparative Analysis, H2 2014 10 Number of Products under Development by Companies, H2 2014 12 Number of Products under Investigation by Universities/Institutes, H2 2014 13 Comparative Analysis by Clinical Stage Development, H2 2014 14 Comparative Analysis by Early Stage Development, H2 2014 15 Products under Development by Companies, H2 2014 16 Products under Investigation by Universities/Institutes, H2 2014 17 Opium (Opioid) Addiction - Pipeline by Alkermes Plc, H2 2014 18 Opium (Opioid) Addiction - Pipeline by Nanotherapeutics, Inc., H2 2014 19 Opium (Opioid) Addiction - Pipeline by Acura Pharmaceuticals, Inc., H2 2014 20 Opium (Opioid) Addiction - Pipeline by Catalyst Pharmaceutical Partners, Inc., H2 2014 21 Opium (Opioid) Addiction - Pipeline by INSYS Therapeutics, Inc., H2 2014 22 Opium (Opioid) Addiction - Pipeline by Camurus AB, H2 2014 23 Opium (Opioid) Addiction - Pipeline by Omeros Corporation, H2 2014 24 Opium (Opioid) Addiction - Pipeline by D&A Pharma SAS, H2 2014 25 Opium (Opioid) Addiction - Pipeline by Reckitt Benckiser Pharmaceutical, Inc., H2 2014 26 Opium (Opioid) Addiction - Pipeline by AllTranz, Inc., H2 2014 27 Opium (Opioid) Addiction - Pipeline by Relmada Therapeutics, Inc., H2 2014 28 Opium (Opioid) Addiction - Pipeline by Celtic Pharmaceutical Holdings L.P., H2 2014 29 Opium (Opioid) Addiction - Pipeline by Foresee Pharmaceuticals, LLC, H2 2014 30 Assessment by Monotherapy Products, H2 2014 31 Assessment by Combination Products, H2 2014 32 Number of Products by Stage and Target, H2 2014 35 Number of Products by Stage and Mechanism of Action, H2 2014 38 Number of Products by Stage and Route of Administration, H2 2014 40 Number of Products by Stage and Molecule Type, H2 2014 42 Opium (Opioid) Addiction Therapeutics - Recent Pipeline Updates, H2 2014 64 Opium (Opioid) Addiction - Dormant Projects, H2 2014 68 Opium (Opioid) Addiction - Discontinued Products, H2 2014 69
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
